Share

February 2016; 3 (1) ArticleOpen Access

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis

Catharina C. Gross, Andreas Schulte-Mecklenbeck, Svenja Klinsing, Anita Posevitz-Fejfár, Heinz Wiendl, Luisa Klotz
First published December 10, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000183
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2191

Share

Article Information

vol. 3 no. 1 e183
DOI: 
https://doi.org/10.1212/NXI.0000000000000183
PubMed: 
26767188
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received July 14, 2015
  • Accepted in final form October 1, 2015
  • First Published December 10, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Catharina C. Gross, PhD*,
    2. Andreas Schulte-Mecklenbeck*,
    3. Svenja Klinsing,
    4. Anita Posevitz-Fejfár, PhD,
    5. Heinz Wiendl, MD and
    6. Luisa Klotz, MD
  1. Catharina C. Gross, PhD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I received speaker honoraria and travel expenses for attending meetings from Genzyme, Novartis Pharma GmbH, and Bayer Health Care.

    Editorial Boards:

    1. Frontiers in Immunology, Review Editor, Since 2015

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. German Research Foundation (DFG), GR3946/2-1, 01/2013-12/2015

    Research Support, Academic Entities:

    1. Innovative Medical Science Grant (IMF-grant) of the medical faculty of the University of M?nster, KL111421, 07/2014-06/2016

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Andreas Schulte-Mecklenbeck*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Svenja Klinsing,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Anita Posevitz-Fejfár, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Genzyme, honoraria and travel costs

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Heinz Wiendl, MD and
    6. Scientific Advisory Boards:

    1. (1) Bayer Healthcare, (2) Biogen Idec, (3) Sanofi- Genzyme, (4) Merck Serono, (5) Novartis, (6) Roche, (7) Tev

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer Vital GmbH, (2) Bayer Schering AG, (3) Biogen, (4) CSL Behring, (5) EMD Serono, (6) Fresenius Medical Care, (7) Sanofi - Genzyme, (8) Merck Serono, (9) Omniamed, (10) Novartis, (11) Teva

    Editorial Boards:

    1. (1) Journal of Clinical Practice, Editorial Board member, since 2006 (2) Journal of Neuroinflammation, Editorial Board member, since 2007 (3) PLOS ONE, Editorial board member, since 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Biogen Idec, (2) Merck Serono, (3) Novartis, (4) Omniamed, (5) Roche (6) Sanofi-Genzyme.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Bayer Healthcare, (2) Bayer Vital, (3) Biogen Idec, (4) Merck Serono, (5) Novartis, (6) Sanofi ? Genzyme, (7) Sanofi US (8) TEVA Pharma

    Research Support, Government Entities:

    1. (1) German Ministry for Education and Research (BMBF), BD120300, Principal Investigator, 2012-2015 (2) German Ministry for Education and Research (BMBF), BD604262, Principal Investigator, 2013-2016 (3) Deutsche Forschungsgesellschaft (DFG), WI 1722/12-1, Principal Investigator, 2012-2015 (4) Deutsche Forschungsgesellschaft (DFG), WI 1722/13-1, Principal Investigator, 2012-2015(5) European Union, BD604219, 2013-2015(6) Deutsche Forschungsgesellschaft (DFG), SFB 1009 TP A3, Principal Investigator, 2012-2015(6) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP A9, Principal Investigator, 2012-2015 (7) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP B1, Principal Investigator, 2012-2015 (8) Deutsche Forschungsgesellschaft (DFG), SFB 128 TP Z2, Principal Investigator, 2012-2015 Else Kr?ner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, Merck Serono, Novartis, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, RE Children?s Foundation.(5) Novartis(6) Sanofi Aventis NovoNordisk)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Else Kr?ner Fresenius Foundation, (2) Fresenius Foundation, (3) Hertie Foundation, (4) RE Children?s Foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Luisa Klotz, MD
    7. Scientific Advisory Boards:

    1. (1) Genzyme

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) CSL Behring, speaker honoraria and travel support

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis, (2) Biogen

    Research Support, Government Entities:

    1. (1) CRC TR128 ?Initiating/Effector versus Regulatory Mechanisms in Multiple Sclerosis ? Progress towards Tackling the Disease?, Project A8

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology, University Hospital Münster, Münster, Germany.
  1. Correspondence to Dr. Klotz: Luisa.klotz{at}ukmuenster.de
View Full Text

Article usage

Article usage: December 2015 to January 2023

AbstractFullPdfSource
Dec 201530615456Highwire
Jan 201642110077Highwire
Jan 2016017094pmc
Feb 20163594385Highwire
Feb 2016013168pmc
Mar 20161233526Highwire
Mar 201608148pmc
Apr 20161381820Highwire
Apr 201608237pmc
May 20161801925Highwire
May 201606032pmc
Jun 201668819Highwire
Jun 201604426pmc
Jul 20162949Highwire
Jul 201604016pmc
Aug 2016751212Highwire
Aug 201603724pmc
Sep 20163776Highwire
Sep 201603016pmc
Oct 20162997Highwire
Oct 201603014pmc
Nov 201641711Highwire
Nov 201603726pmc
Dec 201625104Highwire
Dec 201602714pmc
Jan 2017321412Highwire
Jan 201703413pmc
Feb 201733188Highwire
Feb 201704016pmc
Mar 2017271912Highwire
Mar 201704920pmc
Apr 201732164Highwire
Apr 2017142833pmc
May 201751228Highwire
May 2017133438pmc
Jun 201725227Highwire
Jun 201792421pmc
Jul 201718156Highwire
Jul 2017102224pmc
Aug 201724187Highwire
Aug 201772224pmc
Sep 2017221118Highwire
Sep 201742526pmc
Oct 201727159Highwire
Oct 201782624pmc
Nov 201729166Highwire
Nov 201792329pmc
Dec 20174326Highwire
Jan 201863920Highwire
Feb 201885025Highwire
Mar 201843714Highwire
Apr 201884117Highwire
Apr 201881517pmc
May 201865420Highwire
Jun 201823718Highwire
Jun 201861622pmc
Jul 201843518Highwire
Aug 201855124Highwire
Aug 2018377pmc
Sep 201862013Highwire
Oct 2018135310Highwire
Nov 20187349Highwire
Dec 20186387Highwire
Jan 20199249Highwire
Feb 201953613Highwire
Mar 2019213622Highwire
Apr 201942618Highwire
May 201972716Highwire
Jun 201982821Highwire
Jul 201953528Highwire
Aug 201962423Highwire
Sep 201992314Highwire
Oct 201973622Highwire
Nov 201942320Highwire
Dec 201973726Highwire
Jan 2020142224Highwire
Feb 2020111617Highwire
Mar 2020103324Highwire
Apr 202093018Highwire
May 202010238Highwire
Jun 202031912Highwire
Jul 2020383Highwire
Aug 202061013Highwire
Sep 202092147Highwire
Oct 2020153015Highwire
Nov 2020141519Highwire
Dec 2020111414Highwire
Jan 20219177Highwire
Feb 2021103714Highwire
Mar 202114209Highwire
Apr 202172916Highwire
May 202152820Highwire
Jun 202172710Highwire
Jul 2021122118Highwire
Aug 202110298Highwire
Sep 20216276Highwire
Oct 2021142931Highwire
Nov 2021102631Highwire
Dec 202133717Highwire
Jan 202233317Highwire
Feb 20221369Highwire
Mar 202253315Highwire
Apr 202222810Highwire
May 202224713Highwire
Jun 20222139Highwire
Jul 202271559Highwire
Aug 202212417Highwire
Sep 2022104514Highwire
Oct 202253514Highwire
Nov 2022108229Highwire
Dec 202231768Highwire
Jan 202388920Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me